Who
John M. Evans
CEO
Company insider
Files Form 4 as: CEO, Beam Therapeutics; Director, Verve Therapeutics.
In numbers
- Trades disclosed
- 203
- Buys
- 0
- Sells
- 30
- Bought
- $0
- Sold
- $44.9M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 5 Feb 2020
- Last trade
- 16 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 16 Oct 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $26K25,000 at $1.03 | filing |
| 16 Oct 2026filed 16 Oct 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $600K25,000 at $23.98 | filing |
| 16 Oct 2026filed 16 Oct 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 15 Oct 2026filed 16 Oct 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $26K25,000 at $1.03 | filing |
| 15 Oct 2026filed 16 Oct 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $589K25,000 at $23.57 | filing |
| 15 Oct 2026filed 16 Oct 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $26K25,000 at $1.03 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $791K23,100 at $34.26 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $66K1,900 at $34.84 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $26K25,000 at $1.03 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $791K23,100 at $34.26 | filing |
| 30 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $66K1,900 at $34.84 | filing |
| 29 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $13K18,663 at $0.67 | filing |
| 29 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $6,5276,337 at $1.03 | filing |
| 29 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $472K13,421 at $35.13 | filing |
| 29 Jun 2026filed 1 Jul 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —18,663 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —6,337 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $416K11,579 at $35.91 | filing |
News
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?BEAM · fool.com · 18 Oct 2026Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseBEAM · tickerreport.com · 17 Oct 2026Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressBEAM · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name John M. Evans; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.